AstraZeneca's Ultomiris Showed Zero Relapses In Patients With Chronic Disorder Of Brain, Spinal Cord

AstraZeneca Plc AZN posted detailed results from the Phase 3 CHAMPION-NMOSD trial of Ultomiris (ravulizumab) For neuromyelitis optica spectrum disorder (NMOSD).
NMOSD is an autoimmune disease that affects the central nervous system (CNS), including the spine and optic nerves.
The data showed that Ultomiris significantly reduced relapse risk in adults with anti-aquaporin-4 (AQP4) antibody-positive (Ab+) NMOSD, compared to the external placebo arm from the pivotal Soliris PREVENT clinical trial.
Data showed zero adjudicated relapses were observed among Ultomiris patients with a median treatment duration of 73 weeks (relapse risk reduction: 98.6%). Additionally, 100% of patients receiving Ultomiris remained relapse-free at 48 weeks, compared to 63% of patients in the external placebo arm.
The CHAMPION-NMOSD trial also met key secondary efficacy endpoints, including adjudicated on-trial annualized relapse rate and clinically important change from baseline in the ability to walk.
Price Action: AZN shares are down 0.20% at $57.85 on the last check Thursday.